Pipeline Technologies In Brief
This article was originally published in The Gray Sheet
Executive Summary
Medtronic diabetes care update: Firm will initiate full market release of its Guardian continuous glucose monitoring system, PMA-approved in January, into the $3 bil. blood glucose monitoring market by February 2005, CFO Bob Ryan notes Dec. 1 at the Lazard Life Sciences Conference in New York. In FY 2006, Medtronic plans to launch the next-generation Guardian RT, capable of displaying a patient's "real time" glucose value in five-minute intervals, he added. The company expects to integrate Guardian RT with its Paradigm sensor-augmented insulin pump technology, as part of the effort to develop a closed-loop, external artificial pancreas for diabetic patients by 2008 (1"The Gray Sheet" June 21, 2004, p. 26). Ryan also reported Medtronic is conducting a clinical trial to drive insulin pump therapy penetration. The study will compare insulin pumps with multiple daily injections. The exec believes that a device capable of dropping the HbA1c levels in Type 1 diabetic patients to 7% could lower diabetes healthcare costs by $100 bil. over the next 10 years...
You may also be interested in...
ANS Seeks Neuromodulation Remedy For Migraine Headaches
ANS plans to seek approval to use its neuromodulation platform to treat migraine headaches, according to CEO Chris Chavez
ANS Seeks Neuromodulation Remedy For Migraine Headaches
ANS plans to seek approval to use its neuromodulation platform to treat migraine headaches, according to CEO Chris Chavez
Microstructure Virtual Experiments Could Aid Drug-Delivery R&D, FDAer Says
CDRH's ongoing exploration of material science, and microstructures in particular, could aid development and analysis of drug-delivery systems